Drug Trial Radar · NCT02847338
Comparison of Optimal Hypertension Regimens
Last checked: Nov 19, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
940
Actual
Start
Nov 2016
Primary completion
Oct 2023
Study completion Oct 2023
Sponsor
- Lead sponsor
- Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medical Research Council
- First posted
- Jul 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
High blood pressure (Hypertension) is extremely common and is a major cause of heart disease, kidney disease and stroke. One in three of the UK (United Kingdom) population will require treatment for hypertension at some point in their lives. A healthy lifestyle alone is often not enough to control blood pressure, and drug treatment is usually required. Although a wide variety of drugs are available to treat hypertension, choosing the right kind of tablet or combination of tablets for individual patients is a problem, and therefore many people have poor blood pressure control. Hypertension treatment within the UK is currently selected according to age and self-defined ethnicity (SDE). There are limitations to this approach which include wide variability in the response to hypertension drug classes between people. There is also uncertainty about selecting hypertension drugs for ethnic minorities other than those of African/Caribbean ancestry, for example, South Asians because of a lack of information from trials. In the AIM HY-INFORM study the investigators are looking to recruit equal number of black/caribbean, south asian and white european participants to be able to compare differences in hypertension treatments and ethnicity. The primary objective of this study is to determine if the response to antihypertensive drugs differs by self defined ethnicity.
Conditions
- Hypertension
Interventions
AmlodipineDrug
Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
LisinoprilDrug
Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm. Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm.
AmilorideDrug
Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
ChlortalidoneDrug
Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seated Automated Office Systolic Blood PressureTime frame: Approximately 8 weeks after receiving each treatment up to week 24 for mono therapy patients and up to week 32 for dual therapy patients
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Queen Elizabeth Hospital
Birmingham, United Kingdom
Sandwell & West Birmingham Hospitals NHS Trust
Birmingham, United Kingdom
Heartlands Hospital
Birmingham, United Kingdom
University Hospital Llandough
Cardiff, United Kingdom
University of Glasgow
Glasgow, United Kingdom
Liverpool Heart and Chest Hospital
Liverpool, United Kingdom
William Harvey Research Institute, Barts and the London Medical School
London, United Kingdom
St Thomas' Hospital
London, United Kingdom
St George's Hospital
London, United Kingdom
Hammersmith & Fulham GP Partnership: Richford Gate Medical Practice
London, United Kingdom
Manchester Royal Infirmary
Manchester, United Kingdom
Nottingham University Hospital: QMC Campus
Nottingham, United Kingdom
Lister Hospital
Stevenage, United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambridgeshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.